Close
Solutions
Online Inquiry
Global Services

CAR Targeting Germ Cell Tumor-specific Antigens

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs provides customer with cutting-edge CellRapeutics™ Chimeric Antigen Receptor (CAR) against a series of Germ cell tumor specific antigens, which is based on a great amount of researches and many years of experience. As a reputable service provider, we are dedicated to highly tailored service in order to meet your unique requirements.

CAR Targeting Germ Cell tumor-specific Antigens

Germ cell tumor (GCT) is a rare kind of cancer which derives from germ cells, which can be benign or malignant (cancer). The most common categories are testicular germ cell tumors (seminoma and non-seminoma) and ovarian germ cell tumors, however they can also spread to other parts of the body which leads to various symptoms. The etiology of germ cell tumor is still unclear. The treatment for germ cell tumor usually includes surgery, chemotherapy, radiation, bone marrow transplantation or a combination of these approaches. However, these traditional treatments are not highly effective and can cause the risk of potential complications. In decades, GCT therapy is focused on adaptive immunotherapy, such as chimeric antigen receptor (CAR)-engineered T cells or NK cells, which have been showing remarkable promise for treating cancer. Creative Biolabs, as a leading technology provider, offers a variety of CARs targeting GCT-specific antigens.

With a great team of excellent scientists, we can provide customers with the highest quality bespoke CAR construction service according to your special needs.

Products ordering information

Please note: Besides the CARs targeting GCT-specific antigens listed below, we also provide highly customized service tailored to your research, diagnostic and therapeutic application purposes. We look forward to hearing from you.

Associated malignancy Target antigen Receptor type Product
Ovarian cancer mesothelin scFv-CD28-41BB-CD3ζ CAR-T-3-M321-2BZ
FRα scFv-CD28-41BB-CD3ζ CAR-T-3-M313-2BZ
Bpep scFv-CD28-41BB-CD3ζ CAR-T-3-M402-2BZ
CLDN6 scFv-CD28-41BB-CD3ζ CAR-LC192
B7-H4 scFv--CD28-CD3ζ CAR-LC240
LHR scFv-CD28-41BB-CD3ζ CAR-LC249
MUC16 scFv-CD28-41BB-CD3ζ CAR-MZ194
Alpha(v) beta(6) integrin (αvβ6) Bpep-CD4TM-CD3ζ CAR-MZ229
NKG2D ligands NKG2D receptor-CD28-CD3ζ CAR-MZ233
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.